Drug Trial Radar · NCT04458259
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
88
Actual
Start
Sep 24, 2020
Primary completion
Nov 15, 2024
Study completion Nov 15, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
Conditions
- Neoplasm Metastasis
Interventions
PF-07265807Drug
Given 2 weeks on/1 week off
SasanlimabDrug
Given SC Q3W
AxitinibDrug
Dosed per package label starting with 5 mg PO BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1, 2, and 3: Number of participants with dose limiting toxicities (DLTs)Time frame: Baseline through day 21 or 42
- Parts 1, 2 and 3: Number of participants with treatment emergent adverse events (AEs)Time frame: Baseline through approximately 2 years
- Parts 1, 2, and 3: Number of participants with laboratory abnormalitiesTime frame: Baseline through approximately 2 years
- Part 4: Overall Response Rate (ORR)Time frame: Baseline through approximately 2 years
- Part 4, Cohort 4: Complete Response (CR)Time frame: Baseline through approximately 2 years
Locations
33 sites in 5 countries. Site status is shown where the registry gives one.
Henry Eye Clinic
Fayetteville, Arkansas
Highlands Oncology Group
Fayetteville, Arkansas
Highlands Oncology Group
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
UCI Chao Family Comprehensive Cancer Center
Orange, California
Clinical & Translational Science Institute
San Francisco, California
UCSF Helen Diller Family Comprehensive Cancer Center - Mission Hall
San Francisco, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Rocky Mountain Lions Eye Institute (RMLEI)
Aurora, Colorado
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, Colorado
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado
Community Health Network, Inc.
Indianapolis, Indiana
Community Health Network, Inc.
Indianapolis, Indiana
Community Health Network Cancer Center North
Indianapolis, Indiana
Community Health Network, Inc.
Indianapolis, Indiana
Community Health Network, Inc.
Indianapolis, Indiana
Brigham & Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Dana-Farber Cancer Institute - Chestnut Hill
Newton, Massachusetts
Hackensack University Medical Center
Hackensack, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Duke Eye Center
Durham, North Carolina
Duke University Medical Center, lnvestigational Chemotherapy Service
Durham, North Carolina
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
University Health Network
Toronto, Ontario, Canada
Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale
Naples, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, ROME, Italy
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Díaz
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.